Organic peroxides

Amivas (US), LLC Announces U.S. Launch of Artesunate for Injection for Initial Treatment of Severe Malaria

Retrieved on: 
Tuesday, March 30, 2021

Artesunate for Injection is available for order via:

Key Points: 
  • Artesunate for Injection is available for order via:
    Indicated for the initial treatment of severe malaria in adult and pediatric patients, Artesunate for Injection received marketing approval by the U.S. Food and Drug Administration (FDA) on May 26, 2020.
  • Artesunate for Injection is the first FDA-approved product that Amivas, headquartered in Frederick, Maryland, has introduced to its commercial portfolio.
  • Hospitals may now stock Amivas' Artesunate for Injection for immediate treatment of patients with severe malaria to prevent poor outcomes such as death.
  • Pediatric Use: The safety and effectiveness of Artesunate for Injection for the treatment of severe malaria have been established in pediatric patients.

Global Anti-Malarial Drugs Market is Forecast to Reach US$1035.39 Million in 2024, Witnessing Growth at a CAGR of 3.09%, Over the Period 2020-2024

Retrieved on: 
Tuesday, January 5, 2021

Factors such as rising healthcare expenditure, increasing awareness about diseases, growing population and expanding urbanization are expected to drive the global anti-malarial drugs market.

Key Points: 
  • Factors such as rising healthcare expenditure, increasing awareness about diseases, growing population and expanding urbanization are expected to drive the global anti-malarial drugs market.
  • The growth of the market would be challenged by an upsurge in drugs counterfeiting incidents, side effects of anti-malarial drugs and anti-malarial drug resistance.
  • The global anti-malarial drugs market is segmented on the basis of drug type, antimalarial activity and end-users.
  • Based on the drug type, the global anti-malarial drugs market can broadly be divided into Artemisinin, Antifolate and Aryl aminoalcohol compounds.

Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India

Retrieved on: 
Monday, September 14, 2020

The development of Artemisinin against COVID-19 is dependent on the successful completion of the ARTI-19 clinical trial Artemisinin Intervention trial against COVID-19, which is being initiated globally in Africa, India, and South America.

Key Points: 
  • The development of Artemisinin against COVID-19 is dependent on the successful completion of the ARTI-19 clinical trial Artemisinin Intervention trial against COVID-19, which is being initiated globally in Africa, India, and South America.
  • The companys antisense therapeutic against COVID-19 (OT-101) is meant for hospitalized COVID-19 patients who are no longer responsive to Artemisinin.
  • The global goal of ARTI-19 is enrolled 3,000 patients in the trial to support the approval of Artemisinin against COVID-19.
  • Safety is defined as: 1) Adverse events (AEs) during the study and 2) Serious adverse events (SAEs) during the study.

MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.

Retrieved on: 
Monday, September 14, 2020

The development of Artemisinin against COVID-19 is dependent on the successful completion of the ARTI-19 clinical trial Artemisinin Intervention trial against COVID-19, which is being initiated globally in Africa, India, and South America.

Key Points: 
  • The development of Artemisinin against COVID-19 is dependent on the successful completion of the ARTI-19 clinical trial Artemisinin Intervention trial against COVID-19, which is being initiated globally in Africa, India, and South America.
  • Windlas is Mateons manufacturing partner for clinical trial and commercial product roll out.
  • The global goal of ARTI-19 is enrolled 3,000 patients in the trial to support the approval of Artemisinin against COVID-19.
  • Safety is defined as: 1) Adverse events (AEs) during the study and 2) Serious adverse events (SAEs) during the study.

MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19

Retrieved on: 
Monday, July 20, 2020

ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients.

Key Points: 
  • ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients.
  • If clinically proven effective, Artemisinin can provide relief to overwhelmed medical infrastructure and families affected by the pandemic in resource limited countries.
  • Executive Director, Jennifer Woltz and Director of Research, Justin Omolo at Asili said We are thrilled to partner with Mateon in the effort to study Artemisinin as a potential therapy for the COVID-19 pandemic.
  • Asili is a group of scientists dedicated to improving health care equity in Tanzania.

Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19

Retrieved on: 
Monday, July 20, 2020

ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients.

Key Points: 
  • ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients.
  • If clinically proven effective, Artemisinin can provide relief to overwhelmed medical infrastructure and families affected by the pandemic in resource limited countries.
  • Executive Director, Jennifer Woltz and Director of Research, Justin Omolo at Asili said We are thrilled to partner with Mateon in the effort to study Artemisinin as a potential therapy for the COVID-19 pandemic.
  • Asili is a group of scientists dedicated to improving health care equity in Tanzania.

Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.

Retrieved on: 
Monday, July 13, 2020

Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Key Points: 
  • Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
  • By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.
  • Like other potential COVID-19 therapeutic agents, the efficacy of Artemisinin remains to be tested in well-controlled and sufficiently powered clinical trials.
  • The reported results indicated that Artemisinin had an EC50 = 0.45 ug/ml and Safety Index = 140.

Mateon Therapeutics to fund observational studies of Artemisinin in developing countries

Retrieved on: 
Monday, July 13, 2020

AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Key Points: 
  • AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
  • By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.
  • The company is inviting nonprofits such as non-government organizations to participate in this trial if they have the logistics to participate in observational trials and to distribute the Artemisinin in their home countries.
  • Artemisinin is derived from an abundantly grown herb Artemisia annua L. (Sweet wormwood) and has been used medicinally to treat fevers for centuries in eastern countries.

Amivas (US), LLC Announces FDA Approval of Artesunate for Injection for Treatment of Severe Malaria

Retrieved on: 
Wednesday, May 27, 2020

FDA approval allows Amivas (US), LLC to manufacture, distribute and commercialize Artesunate for Injection.

Key Points: 
  • FDA approval allows Amivas (US), LLC to manufacture, distribute and commercialize Artesunate for Injection.
  • Amivas (US), LLC , specialists in treatments for rare and neglected tropical diseases, including severe malaria, announced today that Artesunate for Injection 110 mg, powder and solvent for solution has received marketing approval by the US Food and Drug Administration (FDA).
  • Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients.
  • Until Amivas' Artesunate for Injection is available in hospitals, healthcare professionals seeking IV artesunate for treatment of patients with severe malaria should contact the CDC for obtaining investigational IV artesunate ( www.cdc.gov/malaria/diagnosis_treatment/artesunate.html (770-488-7788) MondayFriday, 9 am5 pm EST.

Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin

Retrieved on: 
Wednesday, April 8, 2020

Artemisinin is a natural derivative from the Asian herb Artemisia annua and has been used to treat malaria.

Key Points: 
  • Artemisinin is a natural derivative from the Asian herb Artemisia annua and has been used to treat malaria.
  • Artemisinin derived from Chinese herb Artemisia annua L. (Sweet wormwood) has been used medicinally to treat fevers for centuries in China.
  • Dr. Vuong Trieu, President and Chief Executive Officer of Mateon stated: The discovery of Artemisinin through our fruitful collaboration with Golden Mountain Partners could be the solution for COVID-19 pandemic.
  • Like other potential COVID-19 therapeutic agents such as Hydrochloroquine and Remesidivir, the efficacy of Artemisinin remained to be tested in well controlled and sufficiently powered clinical trials but Artemisinin has many advantages against COVID-19.